AECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton by unknown
ORIGINAL PAPER
AECHL-1, a novel triterpenoid, targets tumor neo-vasculature
and impairs the endothelial cell cytoskeleton
Aparajita Dasgupta1 • Mithila A. Sawant1 • Manish S. Lavhale3 •
Lakshmi-Surekha Krishnapati2 • Surendra Ghaskadbi2 •
Sandhya L. Sitasawad1
Received: 5 February 2015 / Accepted: 29 April 2015 / Published online: 8 May 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Tumor angiogenesis is characterized by abnormal
vessel morphology leading to erratic and insufficient delivery
of chemotherapeutics and oxygen, making the tumor core not
only highly hypoxic but also unresponsive toward treatment.
Such hypoxic conditions promote tumor aggressiveness,
leading to the establishment of metastatic disease. Most anti-
angiogenic treatments aim toward the destruction of tumor
vasculature, which proves countereffective by further in-
creasing its aggressive nature.Hence, developing drugswhich
target or regulate these processes might lead to a better de-
livery of chemotherapeutics resulting in tumor shrinkage.
Plant-derived natural compounds having a bioactive ingre-
dient, especially triterpenoids, have been known to possess
anticancer properties. AECHL-1, a recently isolated novel
triterpenoid with proven anticancer potential, is seemingly
noncytotoxic toward HEK 293 and HUVECs. Also, cyto-
toxicity was absent during in vivo studies involving in-
traperitoneal injections with 5 lg/kg body weight AECHL-1
on SCID mice. When used at subtoxic doses, it was found to
be effective in suppression of neo-vessel formation as
demonstrated in the chick chorioallantoic membrane, rat
aortic rings,Matrigel plugs and xenograft tumors implanted in
SCID mice. Tumor vasculature from AECHL-1-treated mice
showed greater mural cell coverage and relatively normalized
architecture. Investigations into the molecular mechanisms
responsible for these observations revealed an effect on the
actin cytoskeleton of stimulated HUVECs as well as the
VEGFR2-mediated MAPK pathway. AECHL-1 could ef-
fectively distinguish between stimulated and nonstimulated
endothelial cells. AECHL-1 could also downregulate HIF-1a
expression and VEGF secretion under hypoxic conditions,
thus reducing the fears of unnecessarily aggravating tumor
metastasis as a result of anti-angiogenic therapy. Results ob-
tained from the aforementioned studies make it clear that
thoughAECHL-1 shows promise in discouraging and pruning
neo-vasculature, it may not affect existing vasculature as the
doses used for the assays are significantly lower than the ones
causing endothelial cell death and has potential to be con-
sidered as a candidate for therapeutic drug development.
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Introduction
Tumor angiogenesis involves the development of new
blood vessels from preexisting ones, as a response to cer-
tain pro-angiogenic signals sent out by masses of neo-
plastic cells in order to sustain their growth into primary
tumors, followed by invasion and metastasis [1–3]. Even
though tumor vasculature has been an attractive therapeutic
target for combating cancer from the time of its recogni-
tion, attempts at targeting it have run into several com-
plexities arising due to increased toxicity, developed
resistance and enhanced tumor aggressiveness as a result of
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the treatments [4–6]. Tumor vasculature has a disregard for
any vascular hierarchy, forms arteriovenous shunts [7], is
tortuous, leaky and tends to run into dead ends with a host
of other structural and functional abnormalities [8–10].
Further insights gained from delving into a deeper under-
standing reveals a stark difference from preexisting normal
vasculature. So, although angiogenesis is a process which
is needed by the host for wound healing, embryonic de-
velopment and development of the corpus luteum, it is now
possible to selectively target these differences and create
drugs which would satisfactorily counter the tumorigenic
state without affecting the functions of the host’s preex-
isting or normally functioning vasculature. Thus, anti-an-
giogenic therapies have seen a multifaceted onslaught of
attacks including agents that neutralize VEGF (e.g.,
Avastin, VEGF-TRAP), target VEGFR2 and other receptor
tyrosine kinases, or inhibit NF-jB and AKT pathways or
even target microtubules [11–13].
In the last decade, many investigators have made efforts
to identify molecules capable of interacting with receptors
expressed in angiogenic vessels, in an attempt to generate
new anti-angiogenic drugs or to obtain ligands for targeted
delivery of other drugs to tumors. Several known anti-an-
giogenic leads have been designed from plant extracts [14–
19], and many triterpenoids isolated from plant extracts
have shown anticancer activities [20]. Synthetic triter-
penoid derivatives, including cyano-3,12-dioxooleana-1,9
(11)-dien-28-oic (CDDO), its methyl ester (CDDO-Me),
and imidazolide (CDDO-Im) derivatives, have shown po-
tential as a potent anti-angiogenic agent both in vitro and
in vivo through the suppression of NF-jB, STAT signaling,
enhancing the transcriptional ability of Smad and also by
interfering with Keap1 activity [21]. In human umbilical
vein endothelial cells, these compounds can inhibit the
activation of the extracellular signal-regulated kinase
ERK1/2 pathway after stimulation with VEGF.
We have recently isolated and characterized a novel
triterpenoid Ailanthus excelsa chloroform extract-1
(AECHL-1) (C29H36O10) from the root bark of Ailanthus
excelsa RoxB (Tree of heaven), a tree belonging to family
Simaroubaceae, widely used in Ayurveda [22, 23] as an
anti-asthmatic, antispasmodic, bronchodilator, anti-colic
pain and anti-diabetic [24]. The compound possesses an-
ticancer activity against a variety of cancer cell lines of
different origin and is less toxic, more selective and more
effective in the treatment of cancer in comparison with
plant-derived anticancer compound paclitaxel and metal-
based compound cisplatin. It is efficacious in inhibiting the
proliferation of a broad range of cancer cells as well as
solid tumors by upregulation of tumor suppressor proteins
and cell cycle arrest along with microtubule disassembly.
In this study, we have demonstrated the anti-angiogenic
potential of AECHL-1 at subcytotoxic concentrations.
AECHL-1 has shown the ability to carry out vascular
pruning and inhibit neo-vascularization in vivo, without
any significant systemic toxicity. The anti-neo-vasculature
effect seems to stem from its interference with the actin
cytoskeletal dynamics and inhibition of VEGF-mediated
VEGFR2 phosphorylation in activated endothelial cells.
Materials and methods
Drugs and cell culture
Human umbilical vein endothelial cells (HUVECs) were
purchased from Lonza and were cultured in EGM-2 media
(Lonza). Cultures weremaintained at 37 Cwith 5 %CO2 in
a humidified incubator. In total, 60–80 % confluent cultures
were used for all experiments. HUVECs were used within
the first five passages. MCF-7 breast adenocarcinoma cell
line was obtained from ATCC. GFR Matrigel and BD Bio-
Coat and BD Matrigel invasion chamber were purchased
from Becton and Dickson (BD Biosciences, USA). VEGF,
ECGS and heparin were from Sigma. AECHL-1 was ex-
tracted, purified and characterized as described earlier [22].
Cell viability assay
Direct interference between different concentrations of
AECHL-1 (0–200 mM) and MTT in a cell-free system was
not observed; therefore, MTT assay was used to test cell
viability in the current system. HUVECs (5000/well) were
cultured in 96-well plates for 24 h and were treated with
different concentrations of AECHL-1 (0–30 lM) for 48 h
at 37 C. After incubation, cell culture media was replaced
with 100 ll of MTT (0.5 mg/ml) solution and was further
incubated at 37 C for 3–4 h. After 4 h, the MTT solution
was discarded and replaced with 100 ll of DMSO and
incubated at room temperature for 15 min on a shaker for
dissolving the formazan crystals, and the absorbance was
measured at 570 nm.
Cell proliferation assay
Proliferation of HUVEC cells was determined by measuring
(3H) thymidine incorporation. Briefly, aliquots of complete
medium containing 5000 cells were distributed into 96-well
tissue culture plates. After 24 h, the media was replaced with
various concentrations of AECHL-1 (0–30 lM). Six hours
after the treatment, 1 lCi/well (3H) thymidine (Board of Ra-
diation and Isotope Technology, Mumbai, India) was added
and the cultures were incubated further for 42 h at 37 C.
Cells were rinsed and collected in scintillation mixture, and
radioactivity incorporated into the DNAwas determined with
a liquid scintillation counter (Canberra Packard).
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Apoptosis detection assay
HUVECs (50,000/ml) were treated with various concen-
trations of AECHL-1 (0–40 mM) for 24 h at 37 C. Cells
were harvested after 24 h, and apoptosis was detected by
using Annexin V-FITC apoptosis detection reagents (BD
Biosciences, USA) using flow cytometry (FACS CALI-
BUR–BD Biosciences, USA). The data were analyzed
using Cell Quest software for determining the percentage
of apoptotic cells.
In vitro tube formation assay
The ability of endothelial cells to form capillary-like
structures/tubes on an extracellular matrix material such as
Matrigel is exploited by one of the most important tests in
determining the pro-/anti-angiogenic effect of any com-
pound [25, 26]. Matrigel 75 ll was added in 96-well plate
and allowed to polymerize at 37 C for 30 min. HUVECs
were seeded at the density of 30,000 cells/well/100ll on
top of the polymerized Matrigel layer. The cells were
treated with either AECHL-1 (5 lM) or VEGF (10 ng/ml)
or their combination. Tube formation was captured at 109
magnification on an inverted microscope (NIKON) after
12 h. Images were analyzed using an ImageJ plugin [27].
Minimum of three fields were analyzed per image.
Scratch wound assay
HUVECs were seeded in 24-well plates and grown up to
nearly 100 % confluency. The cells were scratched with a
pipette tip to create wounds. Treatment with VEGF (10 ng/
ml) and AECHL-1 (5 lM) and in combination with each
other was given in serum-free medium after scratch was
made. Randomly chosen fields were photographed at 109
magnification with an inverted microscope, and the images
were taken at identical locations at the indicated time
points. % cell migration was calculated by comparing final
gap width to initial gap width using image pro-plus. VEGF-
treated wells at the final time point were normalized to
100 % migration.
Cell invasion assay
HUVECs were suspended in serum-free culture medium
and loaded into Matrigel-coated inserts (BD BioCoat,
BD Biosciences, USA) placed in a 24-well plate. The
lower chamber thus created was filled with 500 ll 20 %
FCS-containing culture medium. For experiments in-
volving conditioned medium, the lower chamber was
filled with conditioned medium from MCF-7 cultures
grown for 24 h in the presence or absence of Deferox-
amine (DFO, Sigma-Aldrich, USA) and AECHL-1. After
16 h, the upper surface of the insert was swabbed with a
cotton bud and invasive cells on the lower surface were
fixed in 3.7 % PFA. The inserts were then stained using
1 % crystal violet and imaged (109) using an inverted
microscope (Nikon). ImageJ was used for counting the
invasive cells.
Chick chorioallantoic membrane assay (CAM)
Fertilized domestic chick embryos purchased from Venkys
India Ltd (Pune) were incubated for 3 days at 37 C. A
small hole was punched at the broad end for convenient
embryo placement, and a window was cut open and then
sealed with micropore tape. On day 7, filter paper saturated
with different concentrations of AECHL-1, PBS and Su-
ramin were placed on the CAM, now exposed through the
window. After 48 h, the CAM was dissected out following
formalin fixation and photographed using Leica MZ6
stereomicroscope at 1.69 magnification. Image analysis
for quantification of tertiary and quaternary vessels was
carried out manually.
Ex vivo rat aortic model assay
Wistar rats (6 weeks in age) were killed by CO2 as-
phyxiation according to the Central Animal Ethical Com-
mittee procedures and guidelines (NCCS). Thoracic aorta
was carefully dissected, cleaned of peri-adventitial fat,
spliced into 1–1.5 mm aortic rings and randomized into
Matrigel-coated wells. Rings were overlayed with 100 ll
Matrigel and incubated in EGM-2 media. Cultures were
maintained at 37 C under controlled humid atmosphere
(5 % CO2). The effects of AECHL-1, VEGF and the co-
treatment of VEGF (10 ng/ml) and AECHL-1(5 lM) were
tested by adding them to culture media at day zero. At
different times of culture, rings were photographed under
clear field illumination by using an inverted microscope
with phase contrast mode (Nikon Corp., Tokyo, Ja-
pan).Usually, the time span was 8 days. Images were
analyzed using an ImageJ plugin. At the end of the eighth
day, the culture media was aspirated and assayed for MMP-
2 activity by zymography.
Enzyme-linked immuno sorbent assay (ELISA)
for detection of VEGF
MCF-7 cells were pretreated with AECHL-1 for 2 h and
then incubated in the presence or absence of DFO and
TNF-a for 6 h. Following termination of experiment, cell
culture supernatants were harvested and subjected to
Sandwich ELISA using the R&D quantikine ELISA kit for
determination of secreted VEGF according to the
manufacturer’s instructions.
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ELISA for detection of VEGFR2 phosphorylation
HUVECs grown in 10 mm dishes were preincubated for
4 h in the presence or absence of 5 lM AECHL-1 and
stimulated with 10 ng/ml VEGF for 5 min to induce
VEGFR2 phosphorylation. Cells were then lysed by
sonication in 19 cell lysis buffer (CST) followed by cen-
trifugation. The supernatants were then subjected to ELISA
using the CST PathScan Sandwich ELISA kit for deter-
mination of phosphorylated and total VEGFR2 according
to manufacturer’s instructions. Phosphorylation status of
VEGFR2 receptor was expressed as a ratio of pVEGFR2 to
total VEGFR2.
In vivo Matrigel plug assay
Female SCID mice (6–8 weeks) were maintained in ac-
cordance with the Central Animal Ethical Committee
procedures and guidelines (NCCS). Matrigel plug assay
was performed as described previously, with certain
modifications [21, 28]. Mice were injected subcutaneously
with 500 ll Matrigel containing conditioned media from
MCF-7, 100 ng/ml VEGF, 10 units of heparin and 2 ng/ml
TNF-a (VTH mixture). The injected Matrigel rapidly
formed a single, solid gel plug. The mice were subjected to
intraperitoneal (i.p) injection with either PBS (control) or
5 lg AECHL-1 for 7 days following the day of Matrigel
injection. After 7 days, the skin of the mice was pulled
back to expose the Matrigel plug, which remained intact.
The plug was excised and fixed in neutral buffered for-
malin and embedded in OCT compound (Fisher Health
Care, USA). Cryosections were produced using a cryotome
(Shandon). Quantification of vessel formation was per-
formed by carrying out immunostaining with an anti-CD31
antibody (1:50, BD Bioscience). Briefly, sections were
blocked in 10 % FCS and washed 39 with PBS. Sections
were then incubated with CD31-FITC antibody for an hour
following which were counterstained with DAPI to visu-
alize the nucleus. Images were taken with an Olympus
FluoView confocal microscope at 109 and 609
magnification.
Western blotting
HUVEC and MCF-7 cultures after being subjected to
indicated treatments were scraped and homogenized in
RIPA buffer (20 mM Tris–HCl pH 7.5, 120 mM NaCl,
1.0 % Triton X100, 0.1 % SDS, 1 % sodium deoxycholate,
10 % glycerol, 1 mM EDTA and protease inhibitor cock-
tail, Roche). Proteins were isolated in solubilized form, and
concentrations were measured by Bradford assay (Bio-Rad
protein assay kit). Solubilized protein (30 lg) was dena-
tured in SDS-PAGE sample buffer (Sigma), resolved in
10 % SDS-PAGE and transferred to PVDF (Millipore,
USA) membrane followed by blocking of membrane with
5 % non-fat milk powder (w/v) in TBST (10 mM Tris,
150 mM NaCl, 0.1 % Tween 20). The membranes were
incubated with mouse monoclonal anti-VEGF antibody
(1:1000; SantaCruz) or anti-WAVE-2, pRac/Cdc42, Rac/
Cdc42, pPLC-c1, ERK1/2 and pERK1/2 antibody (1:1000;
Cell Signaling Technology) followed by HRP-conjugated
appropriate secondary antibodies and visualized by an en-
hanced chemiluminescence (Pierce) detection system.
Membranes were stripped and reprobed with GAPDH
primary antibody (1:10000; Sigma) as a protein loading
control.
MCF-7 xenograft studies
Six-week-old female SCID mice were injected subcuta-
neously (s.c) into the dorsolateral flank with 5 9 106MCF-7
cells. When tumor volume reached visible proportions,
animals were treated i.p with either PBS or AECHL-1 5 lg/
kg body weight of the animal for 10 days. After harvesting
tumors, part of the tissue was fixed in neutral buffered for-
malin and subjected to paraffin embedding, while the rest
was either embedded in OCT compound and stored at
-80 C or subjected toWestern blotting. Cryosections were
used to study vascular architecture through IF imaging using
a Zeiss confocal microscope. Vessels positive for CD-31,
with and without associated SMA-positive cells, were ana-
lyzed on 8- and 30-lm-thick sections. Three random fields
were counted in four sections of each tumor specimen, and
quantification was carried out using ImageJ.
Immunofluorescence (IF) by confocal laser scanning
microscopy (CFLSM) and immunohistochemistry
(IHC)
HUVECs and MCF-7 cells were grown on coverslips and
treated with AECHL-1 in combination with VEGF, TNF-a
or Deferoxamine. Cells grown till 70 % confluence were
fixed with 3.7 % paraformaldehyde for 5 min, followed by
permeabilization and blocking in 0.2 % Triton X100 and
5 % milk, respectively. Cells were washed three times with
1x PBS and incubated with primary antibody (HIF-1a,
WAVE-2, IQGAP-1) and their respective Alexafluor-con-
jugated secondary antibodies. Nuclei were labeled using
DAPI. The conditions for incubations, concentration of
primary and the secondary labeled antibodies were stan-
dardized. F-actin was visualized using phalloidin (Mole-
cular Probes) conjugated to either Alexafluor 488 or 647.
The cells were viewed under CFLSM. Tumor vasculature
and pericyte coverage were visualized in 8- and 30-lm-
thick cryosections using CD-31 (1:50 BD Bioscience) and
a-SMA (1:500, Sigma) antibodies, respectively, according
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to established protocols [29, 30]. For studies involving
immunohistochemistry, formalin-fixed paraffin-embedded
(FFPE) sections of tumors were incubated with HIF-1a
antibody (1:50, Sigma) and processed according to previ-
ously described protocol [31].
Zymography
Supernatants collected from rat aortic ring wells were run
on 7.5 % gel made with 0.1 % gelatin concentration. The
supernatant was mixed with reducing agent-free loading
dye. Electrophoresis was carried out until tracking dye was
rundown, and gel was washed in washing buffer and kept
overnight in reconstitution buffer in a CO2 incubator. It
was stained with Coomassie brilliant blue dye for 20 min
and then was destained with 7 % glacial acetic acid. The
zymogram was scanned using a GEL DOC (Syngene).
Statistical analysis
Data were presented as mean ± SEM. The differences
between different treatments were analyzed, using the two-
sided Student’s t test. P values lower than 0.05 were con-
sidered significant.
Results
AECHL-1-inhibited proliferation of HUVECs
without hindering survival
HUVECS were subjected to different concentrations of
AECHL-1 (0–30 lM) for 48 h, and cell viability was de-
termined by MTT assay. With more than 65 % cells re-
maining viable after 48 h, 2–10 lM of AECHL-1 showed
no cytotoxicity. Further increase in AECHL-1 concentra-
tion resulted in decreased viability, but only up to 60 % for
30 lM AECHL-1 (Fig. 1a). The presence of apoptotic
tendency in HUVECs after AECHL-1 treatment was de-
termined by quantifying the exposure of phosphatidyl
serine (PS) on the cell membrane by flow cytometry using
Annexin V-FITC assay. There was no increase seen in the
% of apoptotic cells after AECHL-1 treatment. However,
cell proliferation was seen to be inhibited significantly after
being incubated with varying concentrations of AECHL-1
for 48 h as seen by tritiated thymidine incorporation assay
(Fig. 1b). AECHL-1 5 lM was observed to be responsible
for decreasing the percentage of proliferating cells by
nearly 80 % (Fig. 1c). Noncytotoxic yet anti-proliferative
concentrations of 5–10 lM AECHL-1 were taken for fur-
ther studies. Results suggest that the apparent decrease in
survival as seen by MTT is due to the anti-proliferative
effect of AECHL-1 and not apoptosis.
AECHL-1 inhibits VEGF-induced capillary
structure formation, migration and invasion
by endothelial cells
As clearly illustrated in the review by Goodwin [32], mor-
phogenesis or the formation of capillary-like structures in a
polymerized 3DMatrigel matrix is an indispensable step for
the formation of neo-vasculature. AECHL-1 at 5 lM could
clearly inhibit capillary tube formation both independently
and when stimulated with VEGF (Fig. 2a). Incomplete mesh
formation was observed in wells treated with AECHL-1.
Quantitative analysis revealed a decrease in both the branch
length and the number of branches arising from a single node
as indicated by the branch formation and branching index
data, respectively (Fig. 2b).VEGF stimulation caused an
expected increase in these aforementioned characteristics.
The ability of this compound in inhibiting HUVEC’s
migratory and invasive potential indicated that AECHL-1
could be targeting the cytoskeleton of active endothelial
cells. The percentage of actively migrating cells were 20 %
higher under VEGF stimulation as compared to un-
stimulated or untreated control cells. AECHL-1 could,
however, bring down cell migration by 60, and 40 % on
receiving VEGF stimulation (Fig. 2e, f). Cell invasion as-
say revealed that compared to control, only 72.5 and
36.3 % cells could invade to the lower chamber in response
to serum stimulation after 5 and 7.5 lM AECHL-1 treat-
ment, respectively (Fig. 2c, d).
AECHL-1 performs vascular pruning in the highly
angiogenic chorioallantoic membrane of chick
embryos
Tumor angiogenesis causes excessive and aberrant mi-
crovessel branching as well as growth [8]. The ability to
prune and normalize this abnormal vasculature is a highly
desired quality in any anti-angiogenic treatment of interest
[10, 33]. The anti-angiogenic effect of AECHL-1 was
tested by the conventional CAM assay [34], and it was
observed that all concentrations (5, 10, 20 lg) of AECHL-
1 could bring about a significant decrease in tertiary and
quaternary vessels, which usually form after day 6.
AECHL-1 of concentrations 5 and 10 lg showed vessels
clearly growing away from the site of application (Fig. 3a).
None of these concentrations seemed to affect the primary
or secondary vasculature present prior to receiving treat-
ment. AECHL-1 20 lg and Suramin 5 lg successfully
disrupted the vasculature but increased the tortuosity of the
microvessels along with affecting the primary vasculature.
Filter papers saturated with PBS were used for control
eggs. Branch index: The number of tertiary and quaternary
branches per egg was used as a measure of neo-vessel
formation (Fig. 3b).
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AECHL-1 hinders VEGF-induced microvessel
sprouting and extracellular matrix degradation,
ex vivo
A different line of evidence showing the potential of
AECHL-1 in inhibiting overall angiogenesis is provided by
the ex vivo model of the rat aortic ring assay [35]. Fig-
ure 4a shows that under control conditions the aortic ring
was able to generate neo-vessel sprouting and that the
density of these sproutings increased in the presence of the
pro-angiogenic agent VEGF (10 ng/ml). AECHL-1 5 lM
alone and in combination with VEGF inhibited endothelial
cell sprouting. Quantification of microvessel density per
treatment was depicted by their sprouting and branching
index (Fig. 4b), where the former refers to the number of
sprouts per ring and the latter is a measure of the number of
branches per sprout.
The mechanism employed by endothelial cells for
sprouting and forming neo-vasculature when stimulated
involves the cleaving of extracellular matrix already sur-
rounding the mature vessels. MMP-2 is one such matrix
metalloproteinase known for actively participating in these
activities. Gelatin zymography for conditioned medium
from the wells containing the aortic rings subjected to
AECHL-1 treatment in the presence of VEGF, revealed a
decrease in MMP-2 activity as compared with the wells
containing aortic rings stimulated by VEGF alone (Fig. 4c,
d). AECHL-1 alone, however, could not bring any sig-
nificant decrease in MMP-2 activity.
AECHL-1 discourages tumor cell conditioned
medium-induced angiogenesis in vivo
To determine whether AECHL-1 is capable of blocking
tumor-induced angiogenesis in vivo, an established
in vivo angiogenesis model, the mouse Matrigel plug
assay, was performed. Matrigel containing conditioned
medium from MCF-7 cells was mixed with VTH mixture
and subcutaneously injected into female SCID mice. Mice
were given either PBS or 5 lg/kg body weight AECHL-1,
i.p. Seven days later, the Matrigel plugs were excised and
were photographed. Plugs from mice treated with only
PBS appeared dark red in color. In contrast, plugs from
mice treated with AECHL-1 were pale in color, indicating
no or less blood vessel formation (Fig. 5a). Plugs were
frozen in OCT compound, and their cryosections were
Fig. 1 Effect of AECHL-1 on survival and proliferation of HUVECs.
a HUVECs treated with varying concentrations of AECHL-1 for 48 h,
and cell viability was determined by MTT assay. b HUVECS treated
with varying concentrations of AECHL-1 for 24 h and subjected to
flow cytometry using Annexin V-FITC as a marker of apoptosis.
c HUVECs treated with varying concentrations of AECHL-1 for 48 h,
and cell proliferation was determined by tritiated thymidine assay.
Columns, mean from three independent experiments performed in
triplicate; bars, SE. *P\ 0.05, ***P\ 0.001 versus control alone
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subjected to CD 31-FITC immunostaining. Images were
quantified for vessel formation; angiogenic index and
branching index were used as indicators for branch length
and the number of nodes (Fig. 5 b). Due to almost neg-
ligible invasion of endothelial cells into the plugs in mice
treated with AECHL-1, no nodes could be quantified.
In vitro studies involving conditioned media derived from
AECHL-1-treated breast cancer cells also discouraged
endothelial cell tube formation (see Supplementary
Fig. 1a, b) and invasion (see Supplementary Fig. 1c, d).
These results indicate that AECHL-1 is capable of in-
hibiting breast cancer cell conditioned medium-induced
neo-vessel formation in vivo.
AECHL-1 downregulates phosphorylation
of VEGFR2 and downstream MAPK1/2 activity
To understand the mechanism by which AECHL-1 could af-
fect endothelial cell functions involved in angiogenesis, we
studied the effect of AECHL-1 on VEGFR2-tyr-1175 phos-
phorylation in HUVECs by ELISA. Depending on the site of
phosphorylation, VEGFR2 activates various survival-, pro-
liferation- or migration-related pathways, as a consequence
deciding endothelial cell fate [36]. VEGF-mediated VEGFR2
phosphorylation (tyr-1175) was inhibited considerably by
5 lM AECHL-1 (Fig. 6a). Downstream of VEGFR-2 acti-
vation, among the major pathways responsible for cell
Fig. 2 AECHL-1 inhibits VEGF-induced capillary structure forma-
tion, invasion and migration of endothelial cells. a AECHL-1
inhibited VEGF-induced tube formation of endothelial cells on
Matrigel. b AECHL-1 inhibited HUVEC invasion. Migrated cells
through the membrane were quantified. c AECHL-1 inhibited
HUVEC migration. HUVEC monolayer was scratched by pipette
and treated with or without 10 ng/mL VEGF. Migration is expressed
as % gap closure of VEGF-treated well. Endothelial cells were
photographed (magnification, 910) using Image pro-plus and quan-
tified using ImageJ software for all above-described experiments.
Columns, mean from three independent experiments; bars, SE.
*P\ 0.05; **P\ 0.01; ***P\ 0.001 versus control and
##P\ 0.01; ###P\ 0.001 versus VEGF
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proliferation and migration, phospholipase-C (PLC-c1) is
recruited to the membrane where it is also phosphorylated
which in turn activates the MEK1/2-ERK1/2 signaling cas-
cade [36, 37].This pathway could be inhibitedbypretreatment
of HUVECs with AECHL-1, prior to VEGF induction. In-
terestingly, AECHL-1 alone did not seem to affect MAPK1/2
activation although it could suppress VEGFR2 phosphoryla-
tion (Fig. 6b).Hence, the anti-angiogenic activity ofAECHL-
1 could partly be attributed to the suppression of VEGFR2
phosphorylation upon VEGF stimulation.
AECHL-1 suppresses cell migration by deregulating
actin cytoskeletal dynamics involving
downregulation of certain motility-associated
proteins
To understand the effect of AECHL-1 on actin cytoskele-
ton and cell motility, wound healing assay was performed
on coverslips and then incubated with appropriate anti-
bodies (phalloidin-488 or anti-WAVE-2 or IQGAP1
antibodies). It was seen that untreated cells and cells
stimulated with VEGF showed increased phalloidin inten-
sity (Fig. 7a, b), as compared to cells treated with only
5 lM AECHL-1 or both. Since phalloidin selectively binds
with polymerized forms of actin, F-actin assembly could be
clearly visualized in the former group. Disrupted actin
assembly with the presence of only cortical actin and dis-
appearance of stress fibers was observed in cells treated
with AECHL-1 irrespective of whether they were receiving
VEGF stimulus or not, although cells treated with AECHL-
1 only did show the presence of a weak leading edge and
higher F-actin formation. These cells were also analyzed
for the presence and localization of two important proteins
involved in endothelial cell motility, viz IQGAP1 [38]
(Fig. 7a) and WAVE-2 [39] (Fig. 7b). IQGAP-1 was ob-
served to be present at the leading edges localizing
specifically in either filopodial extensions or active
lamellipodial ruffles in control and VEGF-stimulated cells,
respectively. But due to the abnormal morphology and loss
of filopodial or lamellipodial extensions in the AECHL-1-
Fig. 3 AECHL-1 performs
vascular pruning in
chorioallantoic membrane.
a PBS was used for control and
Suramin (5 lg) as a positive
control. Tertiary vessels turn
away from the site of
application (small white arrow).
Primary vessel turns away from
site of application (white
arrow).b No. of tertiary and
quaternary vessels were
quantified by manually counting
three different areas from each
egg per set. Columns, mean
from three different experiments
with n C 5 per group; bars, SE.
*P\ 0.05; ***P\ 0.05 versus
control
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treated groups, IQGAP1 could be visualized only in the
cytoplasm albeit at lower intensities. WAVE-2, a Wiskott–
Aldrich syndrome family verpolin homology protein, fol-
lowed a similar pattern of localization, limiting itself to the
cytoplasm in the presence of AECHL-1. WAVE-2 ap-
peared to be downregulated by AECHL-1 only upon VEGF
stimulation, as observed through Western blots (Fig. 7c).
Since the Rac1/Cdc42 is responsible for the activation of
the WAVE-2 complex [39] and hence further actin nucle-
ation, leading to capillary lumen formation, we determined
the status of Rac/Cdc42 upon VEGF stimulation and
AECHL-1 treatment [40]. Also, as Rac1 is activated
downstream of VEGFR-2 phosphorylation through the
MAPK pathway, we saw an expected decrease in both
phosphorylated and total Rac levels when ECs were pre-
treated with AECHL-1 followed by VEGF stimulation
[36]. Thus, cells treated with both the effectors fared worse
as compared to cells treated with only AECHL-1. These
results echoed our previous observation that external
stimulation was necessary for AECHL-1-induced inhibi-
tion of migration.
AECHL-1 regulates HIF-1a expression
and translocation both in vivo and in vitro, leading
to a decrease in VEGF secretion in vitro
Tumors are essentially hypoxic due to the lack of oxy-
genation at the core making them more aggressive, an-
giogenic and metastatic, which leads to the release of pro-
angiogenic cytokines and growth factor-like VEGF, among
many others [41]. Hence, the tumor microenvironment
plays an important role in regulating the angiogenic switch.
AECHL-1 could definitively decrease VEGF secretion into
the media by MCF-7 cells in the presence and absence of
DFO (Fig. 8d). DFO acts as HIF-1a stabilizer ensuring
increased secretion of VEGF into the media and mimicking
Fig. 4 AECHL-1 inhibits VEGF-induced microvessel sprouting
ex vivo. Aortic segments isolated from Wistar rats were placed in
the Matrigel-covered wells and treated with VEGF in the presence or
absence of AECHL-1. a Representative images of sprouts from the
margins of aortic rings. Images were captured and quantified using
Image pro-plus and ImageJ software, respectively. b MMP-2 activity
from supernatants assayed using gelatin zymography. Quantification
of band intensities was carried out using ImageJ. Columns, mean
from three independent experiments; bars, SE. *P\ 0.05;
**P\ 0.01 versus control and #P\ 0.05; ##P\ 0.01 versus VEGF
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hypoxia [42]. Images obtained from confocal microscopy-
based IF analysis showed that HIF-1a nuclear translocation
could be hindered when MCF-7 cells were subjected to
AECHL-1 treatment, even after DFO induction (Fig. 8c).
In vitro studies involving xenograft tumors were analyzed
by both IHC and Western blotting. IHC analysis for HIF-
1a showed a notable decrease in HIF-1a staining (Fig. 8a),
when mice were treated with AECHL-1. Nuclear fractions
subjected to Western blotting (Fig. 8b) confirmed that
AECHL-1 could indeed downregulate HIF-1a expression
and translocation in vitro and in vivo.
AECHL-1 prunes tumor vasculature and increases
mural cell involvement in an in vivo xenograft model
Tumor vasculature is characterized by its tortuous mor-
phology, lack of pericyte coverage and leakiness adding to
ineffective oxygenation and failure to deliver
chemotherapeutics [7–10, 29, 30]. Tumors from mice
treated with AECHL-1 had a lower vessel density but
relatively mature vasculature with significantly greater
pericyte coverage as seen in the 8-lm-thick cryosections
(Fig. 9a–c). Analysis of images (Fig. 9d) spanning through
approximately 25–30 lm tissue at intervals of 1 lm re-
vealed the degree of pericyte involvement with the tumor
vasculature in both the treated and control groups. Tumors
from control mice revealed extensively branched vascular
processes with SMA-positive mural cells either extending
away from the vessel with slight or no attachment, whereas
tumors from the treated set had vasculature with regular
morphology and an even layer of mural cells. The ability of
AECHL-1 in pruning aberrantly sprouting vasculature and
stabilizing the remaining ones could play an integral role in
aiding tumor regression and keeping metastasis in check.
Fig. 5 AECHL-1 inhibits MCF-7 conditioned medium-induced an-
giogenesis in vivo. Female SCID mice injected with 0.5 ml of
Matrigel containing conditioned medium and VTH mixture. Mice
were given i.p injections of AECHL-1 at 5 lg/kg of body weight.
After 7 days, mice were killed and Matrigel plugs were excised.
a Representative Matrigel plugs that were given PBS injections
(control) or AECHL-1. Plugs were frozen in OCT compound and
sectioned by a cryotome. Sections were subjected to CD31 FITC
staining immunostaining (pseudo-colored red) and counterstained
with DAPI. Images were taken at 910 and 960 magnification.
b Quantification was carried out by ImageJ. Columns, mean from five
mice per group; bars, SE. ***P\ 0.001 versus control
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Discussion
We have previously demonstrated that AECHL-1 displayed
effective anticancer activity in numerous breast cancer cell
lines among which MCF-7, a breast adenocarcinoma cell
line, succumbed most effectively. AECHL-1 was also re-
ported to have caused microtubule disruption, arrest cell
cycle and induce apoptosis in tumor cells. In vivo
histopathological studies suggested that AECHL-1 was
selective and hence less toxic, but also effective as com-
pared to paclitaxel and cisplatin. Histological examination
of tumor tissue from nude mice showed loss of neo-vas-
cularization and absence of hemorrhagic areas at 5 lg dose
[22]. These results encouraged us to further investigate
whether AECHL-1 could serve as a novel anti-angiogenic
agent at subcytotoxic doses.
Our studies revealed that AECHL-1 is a highly effective
anti-angiogenic agent as demonstrated in both in vitro and
in vivo conditions. Proliferation, migration, morphogenesis
and the ECM degradation all, indispensible stages for neo-
vessel formation by endothelial cells, were checked by
AECHL-1. Interestingly, all of this could be inhibited at a
dose below cytotoxic levels, despite VEGF stimulation.
AECHL-1 also abrogated bFGF (see supplementary
Fig. 2a, b) induced tube formation and conditioned medi-
um-induced neo-vessel formation in vitro, demonstrating
AECHL-10s ability to interfere with pro-angiogenic
stimulations.
The tumor microenvironment is replete with pro-an-
giogenic stimulus involved in attracting and activating ECs
with diverse origins and altered profiles. VEGFR2-medi-
ated pathways are integral to stimulated EC functions;
hence, we looked at the phosphorylation status of
VEGFR2, when ECs are stimulated by VEGF in the
presence of AECHL-1. Downregualtion of VEGFR2
phosphorylation at tyr-1175 partly explains the com-
pound’s ability in inhibiting cell migration, invasion and
proliferation through subsequent inhibition of PLC-c1-
mediated MAPK activity [36, 43, 44]. VEGF-induced
phosphorylation at VEGFR2-tyr-1175 is known to bring
about cell migration through the recruitment of IQGAP1
[45] at the membrane in turn activating the Rac/Cdc42
complex [46, 47]. IQGAP1 is an actin binding scaffold
protein [48], which binds to Rac1 through a GAP-related
domain, thus inhibiting its intrinsic GTPase activity and
activating Rac1 [49–51]. As expected, IQGAP1 accumu-
lated at the leading edge of cells stimulated with VEGF,
but remained restricted to the cytoplasm in cells which
were incubated with AECHL-1. This indicated the possi-
bility that IQGAP-1-mediated Rac/Cdc 42 signaling might
be targeted by AECHL-1. To further confirm the inhibition
of Rac-/Cdc42-mediated signaling, we looked at both
Rac1/Cdc42 activation and WAVE-2 a Wiskott-Aldrich
Syndrome Protein family Verprolin—homologous proteins
(WAVEs). WAVE proteins are known to act downstream
of Rac/GTPase (Rho family small GTPase) [36], connect-
ing Rac activation to the induction of Arp2/3-mediated
actin polymerization [52, 53]. WAVE-2 was indeed seen to
avoid cell membranes and showed a decrease in expression
when incubated with AECHL-1 prior to VEGF stimulation
as compared to VEGF-stimulated cells. This observation
could be attributed to the inhibition of Rac1/Cdc42 acti-
vation. The fact that cells treated with only AECHL-1 did
not show a decrease in either Rac or WAVE-2 levels could
imply that AECHL-1 may be involved in targeting Actin
cytoskeleton dynamics much more effectively in response
Fig. 6 Effect of AECHL-1 on VEGFR2-mediated MAPK signaling.
a Quantification of VEGFR2 phosphorylation by ELISA. Fold change
indicates the ratio of phosphorylated to nonphosphorylated VEGF.
Cells were pretreated with AECHL-1 for 4 h and stimulated with
VEGF for 5 min. b Cells were pretreated with AECHL-1 for 4 h and
stimulated with VEGF for 25 min. Cells were harvested, and Western
blotting was performed for detection of pPLC-c1, pMEK1/2 and
pERK1/2. Membrane was stripped and reprobed with Total MEK1/2,
ERK1/2 and GAPDH to indicate equal loading. Columns, mean from
three different experiments performed in triplicate; bars, SE
Angiogenesis (2015) 18:283–299 293
123
to external stimuli. Further validation for this theory is
derived from the observation that cells treated with only
AECHL-1 fared better than cells receiving both the treat-
ments. The former showing the presence of a leading edge
and relatively better F-actin organization.
It is also interesting to note the difference in the pattern
of actin cytoskeleton assembly in response to different
treatments in these cells. Ruffled lamellipodial leading
edges served the purpose of cells at the leading edge re-
sponding to VEGF stimulus better, whereas untreated cells
Fig. 7 Effect of AECHL-1 on microfilament dynamics and motility-
associated proteins. HUVECs were grown on coverslips till conflu-
ency and scratched with a pipette tip. Cells were pretreated with
AECHL-1 for 4 h and then stimulated with VEGF and incubated for
9 h. Coverslips were then fixed and processed for immunostaining.
Immunofluorescence analysis of HUVECs stained with phalloidin
conjugated with Alexa Fluor 488 and a anti-IQGAP1 antibody b anti-
WAVE-2 antibody. Membrane ruffles indicate active lamellipodial
edge (white arrow). Images were taken by a confocal microscope at
960 magnification. c Also at the indicated time (9 h), cells were
harvested and subjected to Western blotting for detection of WAVE-2
and pRac/Cdc42. Membrane was stripped and reprobed with total
Rac/Cdc42 and GAPDH to indicate equal loading
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although sporting a healthy morphology showed the pres-
ence of laterally arranged stress fibers, usually seen in cells
with strong focal adhesions. This could be indicative of
cells responding to only a scratch-inflicted injury on the
monolayer than an external stimulus.
It has been seen that endothelial cells in tumor vascu-
lature are comparatively more proliferative than their
counterparts in mature adult vasculature and hence are
susceptible to vasculature-disrupting drugs at low doses
[54, 55]. Thus, it is not surprising that AECHL-1 could be
exploiting this differential response phenomenon in tar-
geting actin cytoskeletal dynamics, motility-related pro-
teins actively proliferating stimulated endothelial cells.
Breakdown of the extracellular matrix (ECM) by Matrix
Metalloproteinases encourages endothelial cell sprouting
and allows for greater freedom in motility and invasion.
AECHL-1 was seen to inhibit MMP-2 activity in response
to VEGF stimulation in the rat aortic ring assay. This assay
Fig. 8 AECHL-1 regulates HIF-1a expression and translocation both
in vivo and in vitro, leading to a decrease in VEGF secretion in vitro.
MCF-7 cells were injected in the right flank of SCID mice(n = 5 per
group) as described in ‘‘Materials and methods.’’ a Tumor tissues
were fixed in formalin and embedded in paraffin for immunohisto-
chemistry using anti-HIF-1a antibody. b Western blotting using
nuclear extracts from tumor tissue revealed a decrease in HIF-1a
expression. c AECHL-1 treatment of MCF-7 cells decreased HIF-1a
stabilization and nuclear translocation as indicated by immunofluores-
cence studies (960). d AECHL-1 treatment resulted in decreased
secretion of VEGF, as determined by ELISA. TNF-a (100 lM) was
used as a positive control. Columns, mean from three different
experiments; bars, SE. *P\ 0.05 versus control; ##P\ 0.01 versus
Deferoxamine (200 lM) and $$P\ 0.01 versus TNF-a
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also allows the study of endogenous growth factors being
secreted into the media by the implants and the interaction
of their outgrowths with vasculature supportive cells such
as pericytes and smooth muscle cells over a period of time.
This provides much needed insight into the mode of action
of our compound. Apparently, AECHL-1 could suppress
angiogenic sprouting in aortic rings not receiving VEGF
stimulus, maybe due to reduced secretion of pro-angio-
genic cytokines and growth factors and the ability of
AECHL-1 to interfere in events other than cytoskeletal
dynamics. This observation prodded us to investigate
whether AECHL-1 could downregulate pro-angiogenic
growth factor expression in tumorigenic cells. We observed
that VEGF secretion could be downregualted by AECHL-1
Fig. 9 Effect of AECHL-1 on tumor angiogenesis. MCF-7 cells were
injected in the right flank of SCID mice (n = 5 per group) as
described in ‘‘Materials and methods.’’ Eight-micrometer cryosec-
tions were stained for CD-31 to a visualize and b quantify vessel
density (920), or CD-31 and a-SMA to c visualize and d quantify
pericyte coverage of tumor vasculature. e Organization of mural cells
in AECHL-1-treated and control tumors as analyzed in the 30-lm
cryosections doublestained for CD-31 and a-SMA (940, projected
stacks).Control vessels show decreased mural cell support with
treated vessels showing higher mural cell investment. Arrows, SMA?
cells extending away from vessel. Arrowheads, SMA? cells without
any associated vessels. Columns, mean from five mice per group;
bars, SE. **P\ 0.01; ***P\ 0.001 versus control
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even when hypoxia-mimicking agents such as DFO or pro-
angiogenic cytokines such as TNF-a [56] were adminis-
tered. Hypoxia causes the stabilization of HIF-1a, which
directly promotes VEGF expression by binding upstream
of its promoter [57].
Most anti-angiogenic agents have been implicated to be
countereffective by making tumors even more hypoxic and
hence aggressive by destructing tumor vasculature com-
pletely [58, 59]. This also results in ineffective delivery of
therapeutic agents to the tumor. The practice of vessel
normalization advocates the necessity of aberrant and tor-
tuous tumor vasculature to be pruned and normalized aid-
ing in delivery of required therapeutics and oxygen, leading
to reduced hypoxia and faster tumor regression [10, 33]. In
our in ovo CAM assay, the primary and secondary vascu-
lature were seen to be unaffected at 5 and 10 lg doses, but
performed extensive vascular pruning of tertiary and qua-
ternary vessel. At higher doses, AECHL-1 and Suramin
treatment resulted in aberrantly disrupted vasculature along
with disturbed primary vasculature making these
treatments an unattractive option for further perusal. While
in tumors harvested from AECHL-1-treated mice, the
vessels were supported by a firm layer of pericytes indi-
cating mature vasculature, since abnormal neo-vasculature
shows a lack of pericyte involvement. Data arising out of
both in ovo and in vivo assays bode well for a prospective
therapeutic agent, as it hints toward the elimination as
wells as a possibility for normalization of erratic vascula-
ture in response to pro-angiogenic stimuli, without harm-
ing, preexisting vasculature. The decrease in HIF-1a levels
in MCF-7 xenograft tumors could have a multipronged
effect where it not only abates concerns about tumor ag-
gressiveness caused by the severe hypoxic conditions
generated by anti-angiogenic treatments but also increases
the chances of vascular normalization by increasing peri-
cyte coverage, since HIF-1a directly influences VEGF
production and in turn antagonizes pericyte involvement
with ECs by activating VEGFR2 and downregulating
PDGFR-b signaling through a VEGFR2–PDGFR-b com-
plex [60]. The extensive perivascular support observed in
Fig. 10 Schematic
representation of the molecular
mechanisms involved in
regulation of endothelial cell
function and tumor
angiogenesis by AECHL-1
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tumors from AECHL-1-treated mice could also be due to
the decrease in HIF-1a levels. The above-described
molecular mechanisms thus encompass the multiple targets
of AECHL-1 involved in impairing stimulated endothelial
cell function and tumor vessel normalization (Fig. 10).
In conclusion, the observation that AECHL-1 portrays
an anti-angiogenic role at subcytotoxic doses, by selec-
tively targeting aberrant and immature vasculature, can be
exploited further for therapeutic purposes.
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